Education
About Us
Working with TipRanks
Follow Us
Regulus Therapeutics Inc (RGLS)
:RGLS
RGLS Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Regulus News
RGLS FAQ
What was Regulus Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Regulus Therapeutics Inc’s market cap?
Currently, no data Available
When is Regulus Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regulus Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Regulus Therapeutics Inc overvalued?
According to Wall Street analysts Regulus Therapeutics Inc’s price is currently Undervalued.
Does Regulus Therapeutics Inc pay dividends?
Regulus Therapeutics Inc does not currently pay dividends.
What is Regulus Therapeutics Inc’s EPS estimate?
Regulus Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regulus Therapeutics Inc have?
Currently, no data Available
What happened to Regulus Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regulus Therapeutics Inc?
Currently, no hedge funds are holding shares in RGLS
Company Description
Regulus Therapeutics Inc
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. The company operates in the biotechnology sector, primarily working on therapies to address unmet medical needs in various diseases. Regulus's core offerings include a pipeline of microRNA therapeutics aimed at treating conditions like genetic kidney diseases and other serious health issues.
Regulus (RGLS) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Ownership Overview
―
Insiders
28.64%
Mutual Funds
― Other Institutional Investors
71.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---